InvestorsHub Logo
Followers 75
Posts 4668
Boards Moderated 0
Alias Born 09/06/2003

Re: DewDiligence post# 117

Wednesday, 09/08/2010 12:17:36 PM

Wednesday, September 08, 2010 12:17:36 PM

Post# of 125

Even if interferons stay around in HCV therapy for many years to come, $1B in annual Lambda sales is a tall order, IMO.



Why? If IFN-L pans out (substantially better side effect profile and better efficacy - both strongly hinted at in ph i data) then it should pick of most of the IFN in HCV market fairly quickly. Witness the very rapid enrollment in the trials.